Resistant thrombocytopenia in an HIV and hepatitis C patient: treatment response with novel agent eltrombopag

  • Rajakrishnan Vijayakrishnan | vrajakrishnan@gmail.com
  • Sourbha Dani
  • Aparna Ramasubramanian
  • Rekha Nair
  • Tony M. Samaha

Abstract

HIV-associated thrombocytopenia is a dis- ease which can be recurrent to standard therapy which includes highly active antiretroviral therapy (HAART) therapy, steroids and immunoglobulin. We report a patient with HIV and hepatitis C who presented with resistant thrombocytopenia. Treatment with Eltrombopag – a thrombopoeitin receptor agonist showed initial good response with recurrence of thrombocytopenia. This novel agent could be considered as a treatment option prior to splenectomy and may be useful as a tempo- rizing measure.

Google Scholar

Google Scholar

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2011-03-29
Info
Issue
Section
Case Reports
Keywords:
Thrombocytopenia, Eltrombopag, Human Immunodeficiency Virus, Hepatitis C, Hematologic Diseases
Statistics
  • Abstract views: 1703

  • PDF: 99
  • HTML: 90
How to Cite
Vijayakrishnan, R., Dani, S., Ramasubramanian, A., Nair, R., & Samaha, T. M. (2011). Resistant thrombocytopenia in an HIV and hepatitis C patient: treatment response with novel agent eltrombopag. Clinics and Practice, 1(1), e5. https://doi.org/10.4081/cp.2011.e5